Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotine replacement-ECOG-ACRIN Cancer Research Group
- Development stage
- Unknown
- Lead developer
- ECOG-ACRIN Cancer Research Group
- Modality
- Small Molecules
- Administration
- Buccal, Transdermal
01
Overview
Nicotine replacement therapy (NRT) in the context of the ECOG-ACRIN Cancer Research Group's Smoke-Free Support Study 2.0 (EAQ171CD) involves the use of FDA-approved nicotine patches and lozenges to facilitate smoking cessation in patients recently diagnosed with cancer. Nicotine acts as a small molecule agonist at nicotinic acetylcholine receptors (nAChRs) in the brain, providing a controlled dose of nicotine to reduce the severity of withdrawal symptoms and cravings associated with tobacco cessation. In this Phase II trial, NRT is delivered as part of a Virtual Intervention Treatment (VIT) arm, which combines up to 12 weeks of pharmacotherapy with virtual counseling sessions. The study aims to evaluate the effectiveness of this integrated, community-based tobacco treatment approach compared to standard quitline referrals.
- Other names
- Nicotine Replacement TherapyNRTEAQ171CD interventionEAQ-171CD interventionEAQ 171CD intervention
02
Targets
CHRNA7 (α7 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)Muscle-type nicotinic acetylcholine receptor
Beyond the preview
Go deeper on nicotine replacement-ECOG-ACRIN Cancer Research Group.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotine replacement-ECOG-ACRIN Cancer Research Group.